Actavis controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
2022
UK hydrocortisone tablet pricing case
The UK Competition and Markets Authority confirmed findings that Actavis had abused a dominant position by charging excessive and unfair prices for hydrocortisone tablets and by entering agreements that impeded potential competition. The findings concerned the supply of medicines to the National Health Service and covered conduct associated with substantial price increases over the preceding years.